Galmed Pharmaceuticals share price logo

Galmed Pharmaceuticals

NASDAQ: GLMD

$4.63

+0.80

(+21.05%)

as on

Bell Icon

This instrument is not available for trading on the INDmoney app

Galmed Pharmaceuticals Stock Performance

as on September 10, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $3.82
    $4.60
    downward going graph

    17.49%

    Downside

    -0.65%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.29
    $13.20
    downward going graph

    28.97%

    Downside

    185.10%

    Upside

    downward going graph

Galmed Pharmaceuticals share price movements today

Previous Close
$3.83
Open
$3.88
Volume
248.3K
Market Cap
$4.3M
Day's Low - High
$3.82 - $4.60
52 Week Low - High
$3.29 - $13.20

Galmed Pharmaceuticals Historical Returns

1 Month Return
-20.99 %
3 Month Return
-29.01 %
1 Year Return
-61.37 %
3 Year Return
-95.38 %
5 Year Return
-99.92 %

Galmed Pharmaceuticals Stock Fundamentals & Key Indicators

Check Galmed Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.3M

EPS (TTM)

-2

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.27

Industry PE ratio

-1.46

PEG Ratio

-0.00

EBITDA

-11.2M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-64.10%

Galmed Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Galmed Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Neutral$4.3M-99.92%-0.270.00%0.00%
StrongBuy$41.0B501.04%-21.590.00%0.00%
StrongBuy$141.7B208.09%32.2786.04%0.00%
Neutral$88.5B-36.40%-27.78-12.57%0.00%
Buy$95.5B45.26%19.7685.77%0.40%

Stock Returns calculator for Galmed Pharmaceuticals Stock including INR - Dollar returns

The Galmed Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Galmed Pharmaceuticals investment value today

Current value as on today

₹48,743

Returns

-₹51,257

(-51.26%)

Returns from Galmed Pharmaceuticals Stock

-₹54,429 (-54.43%)

Dollar Impact

₹3,172 (+3.17%)

Analyst Recommendation on Galmed Pharmaceuticals Stock

Based on 1 analysts

HOLD

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'HOLD' rating for Galmed Pharmaceuticals. Average target price of $12

Galmed Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Galmed Pharmaceuticals.

What analysts predicted

61.42%UPSIDE

Target Price

$12

Current Price

$4.63

Analyzed by

1 Analysts

Target

$12.00

Galmed Pharmaceuticals target price $12, a slight upside of 61.42% compared to current price of $4.63. According to 1 analysts rating.

Indian Investors' Interest in Galmed Pharmaceuticals Stock

Search interest for Galmed Pharmaceuticals Stock has increased by 127% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:127% versus previous 30 day period

Galmed Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
-
-
-
Operating Income
-2
-1
-1
-2
-1
-1
-2
-2
-3
-2
EBITDA
-2
-1
-1
-1
-2
-1
-2
-1
-4
-2
Interest Expense
-
-
-
-
0
-
-
-
-
-
Depreciation
0
0
0
-
-
-
-
-
-
-
Income Before Tax
-2
-1
-1
-1
-3
-1
-2
-1
-4
-1
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-2
-1
-1
-1
-3
-1
-2
-1
-4
-1
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Galmed Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
2
-
-
-
-
-
-
-
Gross Profit
1
2
-
-
-
-
-
-
-
Operating Income
-12
-10
-22
-30
-32
-17
-7
-6
-8
EBITDA
-12
-10
-22
-30
-32
-17
-6
-7
-10
Interest Expense
0
0
0
0
0
0
0
0
-
Depreciation
0
0
0
0
0
0
0
0
-
Income Before Tax
-12
-9
-20
-28
-32
-17
-6
-7
-10
Income Tax Expense
-
0
-
-
-
-
-
-
-
Net Income
-12
-9
-20
-28
-32
-17
-6
-7
-10
Net Profit Margin
100.00%
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Galmed Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-2
-1
-1
-1
-3
-1
-2
-1
-4
-1
Operating Cash Flow
0
-1
-1
-1
-1
-1
-1
-1
-1
-2
Investing Cash Flow
2
0
1
0
-3
0
-4
0
1
0
Financing Cash Flow
-
-
-
8
0
1
6
0
1
-
Change in Cash
1
-1
0
7
-5
0
0
-1
0
-2

Galmed Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-12
-9
-20
-28
-32
-17
-6
-7
-10
Operating Cash Flow
-12
-9
-14
-26
-32
-18
-6
-5
-6
Investing Cash Flow
6
-60
6
16
11
17
0
-1
-3
Financing Cash Flow
15
80
0
0
17
0
6
8
9
Change in Cash
9
11
-8
-8
-4
0
0
1
0

Global Institutional Holdings in Galmed Pharmaceuticals

Check out the Institutions with significant holdings in Galmed Pharmaceuticals.

Funds
Holdings
Wells Fargo & Co
0.00%
ZRC WEALTH MANAGEMENT, LLC
0.00%
ZRC WEALTH MANAGEMENT, LLC
0.00%
BNP Paribas Arbitrage, SA
0.01%
XTX Topco Ltd
0.29%

Galmed Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 02 September

    Thu, 01:57 AM

    -

    Galmed Pharmaceuticals adjourns shareholder meeting due to lack of quorum, rescheduled for September 3, 2026.

    Thu, 02:48 AM

    -

    Galmed Pharmaceuticals reports higher R&D spending and cash decline, with accumulated deficit widening to $215.4 million.

Insights on Galmed Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 477.3% return, outperforming this stock by 543.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 30.4% return, outperforming this stock by 125.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, GLMD stock has moved down by -19.4%

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
OrganisationGalmed Pharmaceuticals
Headquarters16 Abba Hillel Road, Ramat Gan, Israel, 5250608
IndustryBiotechnology
CEOMr. Allen Baharaff

Key Management of Galmed Pharmaceuticals

Name

Title

Dr. Tali Gorfine

Medical Consultant

Mr. Allen Baharaff

Co-Founder, President, CEO & Chairman

Mr. Doron Cohen

Chief Financial Officer

Mr. Guy Nehemya

COO & Data Protection Officer

Mr. Yohai Stenzler CPA

Chief Accounting Officer

Dr. Liat Hayardeny MBA, Ph.D.

Chief Scientific Officer

FAQs

What is Galmed Pharmaceuticals share price today?

Galmed Pharmaceuticals share price today is $4.63 as on at the close of the market. Galmed Pharmaceuticals share today touched a day high of $4.60 and a low of $3.82.

What is the 52 week high and 52 week low for Galmed Pharmaceuticals share?

Galmed Pharmaceuticals share touched a 52 week high of $13.20 on and a 52 week low of $3.29 on . Galmed Pharmaceuticals stock price today i.e. is closed at $4.63,which is 64.92% down from its 52 week high and 40.78% up from its 52 week low.

What is Galmed Pharmaceuticals's market capitalisation today?

Galmed Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Galmed Pharmaceuticals Stock (GLMD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Galmed Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Galmed Pharmaceuticals Stock (GLMD) from India?

Indian investors can start investing in Galmed Pharmaceuticals (GLMD) shares with as little as ₹94.9000015258789 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.00 in Galmed Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Galmed Pharmaceuticals share’s latest price of $4.63 as on September 10, 2026 at 8:46 am IST, you will get 2.1598 shares of Galmed Pharmaceuticals. Learn more about fractional shares .

What are the returns that Galmed Pharmaceuticals has given to Indian investors in the last 5 years?

Galmed Pharmaceuticals stock has given -99.92% share price returns and 27.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?